Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2018-12-12 Director's Dealing
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-12-12 English
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a previously filed Form 8-K. It is a current report filed pursuant to the Securities Exchange Act of 1934. The content discusses an amendment related to an acquisition disclosure and the removal of certain financial statement requirements. The document is relatively short (3257 characters) and serves as an update or correction to a prior filing rather than a full financial report or detailed announcement. It does not contain financial statements or detailed financial analysis but rather regulatory compliance information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2018-12-06 English
SC 13D/A
Major Shareholding Notification
2018-11-13 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes entering into license agreements and related business developments, which are typical disclosures in an 8-K. It is not a full financial report, audit, or earnings release, nor is it a meeting material or voting result. The document length is 4171 characters, which is relatively short and consistent with an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS), as 8-Ks are general regulatory announcements that do not fit into more specific categories.
2018-11-13 English
10-Q
Interim / Quarterly Report Q3 2018
2018-11-08 English
8K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2018, by Ligand Pharmaceuticals. It specifically states in Item 2.02 that the company issued a press release announcing financial results for the three and nine months ended September 30, 2018. The document includes the press release as Exhibit 99.1. The content is a current report announcing quarterly financial results, which aligns with an Earnings Release. The document length is 3070 characters, which is short and consistent with an 8-K earnings release filing rather than a full interim report. Therefore, the appropriate classification is Earnings Release (ER).
2018-11-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.